Compliance as an explanatory variable in clinical trials

Journal of the American Statistical Association

Volumn 86, Issue 413, 1991, Pages 9-17

  Efron, B ^a   Feldman, D ^b  

^a STANFORD UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84950442333     PISSN: 01621459     EISSN: 1537274X     Source Type: Journal    
DOI: 10.1080/01621459.1991.10474996     Document Type: Article

References (10)

1. Chevalley, C. and Urquhart, J. (1987), “Medication Event Monitoring to Project Impact of Patients’ Dosing Errors on Clinical Trial Results,” Abstracts of the 8th Conference, International Society of Clinical Biostatistics, Gothenburg: Sweden.
2. Coronary Drug Research Group (1980), “Influence of Adherence to Treatment and Response of Cholesterol on Mortality in the Coronary Drug Project,” New England Journal of Medicine, 302, 1038–1041.
3. Efron, B. (1988), (in press) “Regression Percentiles Using Asymmetric Squared Error Loss,” Statistica Sinica.
4. Holland, P. (1986), “Statistics and Causal Inference” (with discussion), Journal of the American Statistical Association, 81, 945–970.
5. Holland, P. (1988), “Causal Inference, Path Analysis, and Recursive Structural Equations Models,” Sociological Methodology 1988, C. Clogg.
6. Koch, G., Aman, I., Davis, G., and Gillings, D. (1982), “A Review of Some Statistical Methods for Co variance Analysis of Categorical Data,” Biometrika, 38, 563–595.
7. Lipid Research Clinic Program (1984), “The Lipid Research Clinics Coronary Primary Prevention Trial Results, Parts I and II,” Journal of the American Medical Association, 251, 351–374.
8. p,” Technometrics, 15, 661–675.
9. Scheffé, H. (1959), The Analysis of Variance, New York: John Wiley.
10. Urquhart, J., and Chevalley, C. (1988), “Impact of Unrecognized Dosing Errors on the Cost and Effectiveness of Phamaceuticals,” Drug Information Journal, 22, 363–378.